PharmaRadar360

PharmaRadar360

🇺🇸·Aug 31Research

NCT02257736: An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Study type: INTERVENTIONAL. Phase: PHASE3.

Publisher

C
ClinicalTrials.gov

USA

This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
ClinicalTrials.gov
Region
USA
Scope
Research
Published
August 31, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Study type: INTERVENTIONAL. Phase: PHASE3.

Source route

Continue on clinicaltrials.gov

Leave the platform to read the original full article on the publisher site.

Source: ClinicalTrials.gov

Scope: Research

Open original article
NCT02257736: An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | PharmaRadar360